Compare GO & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GO | ARVN |
|---|---|---|
| Founded | 1946 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 732.0M | 658.2M |
| IPO Year | 2019 | 2018 |
| Metric | GO | ARVN |
|---|---|---|
| Price | $9.30 | $7.67 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 19 |
| Target Price | $11.30 | ★ $15.05 |
| AVG Volume (30 Days) | ★ 2.6M | 649.0K |
| Earning Date | 05-13-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,688,759,000.00 | $262,600,000.00 |
| Revenue This Year | $2.48 | N/A |
| Revenue Next Year | $3.91 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 7.26 | N/A |
| 52 Week Low | $5.66 | $6.06 |
| 52 Week High | $19.41 | $14.22 |
| Indicator | GO | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 60.10 | 38.70 |
| Support Level | $9.01 | $7.35 |
| Resistance Level | $9.44 | $10.18 |
| Average True Range (ATR) | 0.44 | 0.43 |
| MACD | 0.06 | 0.08 |
| Stochastic Oscillator | 62.82 | 33.10 |
Grocery Outlet Holding Corp is a grocery store operator in the United States. It is a retailer of quality, name-brand consumables and fresh products sold through a network of independently operated stores. The stores are run by Entrepreneurial independent operators which create a neighborhood feel through personalized customer service and a localized product offering.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.